Cue Biopharma, Inc. (CUE) SEC Filings

Cue Biopharma, Inc. (CUE) reports an amended Form 4 for director Pamela Garzone to correct a prior administrative calculation error in a grant of restricted stock units (RSUs). The original report showed 21,800 shares acquired; the correct amount is 18,900 shares, which is now also the total beneficially owned following the transaction. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to her continued service with the company.

Cue Biopharma, Inc. (CUE) is the subject of a Schedule 13D report by its President, Chief Executive Officer and director, Dr. Shao-Lee Lin, who beneficially owns 467,166 shares of Common Stock, representing 6.2% of the class. This consists of 378,458 shares held directly, 20,471 shares issuable upon settlement of vested RSUs within 60 days, and options exercisable for up to 68,237 shares within 60 days. The percentage is based on 7,405,436 shares outstanding as of August 18, 2026, plus the RSU and option shares counted for beneficial ownership.

Dr. Lin’s equity arises largely from employment compensation, including a fully vested 327,537-share RSU grant in May 2026, a separate 327,537-share RSU grant vesting quarterly over 48 months, and 327,537 performance stock units that vest in three tranches tied to stock price hurdles of $33.00, $38.50, and $44.00 for five consecutive trading days. A trust for her benefit also purchased Pre-Funded Warrants for up to 90,906 shares at an exercise price of $0.001 and Warrants for up to 45,453 shares at $11.00, for an aggregate purchase price of $999,966, but these instruments are subject to a 4.99% Beneficial Ownership Blocker and are not currently exercisable.

Cue Biopharma, Inc. officer Sumita Ray reported a derivative PSU exercise and related share sales on August 13, 2026. A block of 18,196 common shares was issued upon settlement of performance stock units, while a matched 18,196 underlying derivative position was exercised and disposed.

To fund tax withholding from this vesting, Ray reported sell-to-cover transactions totaling 8,829 shares, including 2,383 shares at a weighted average price of $29.37 (range $28.97–$29.96), 6,442 shares at a weighted average price of $30.35 (range $29.99–$30.97), and 4 shares at $31.13. The PSUs vest in three equal tranches tied to stock-price targets of $33.00, $38.50, and $44.00 achieved over five consecutive trading days within 24 months of grant; one-third settled on August 13, 2026, with the remaining two-thirds expected to settle upon achievement of the higher targets.

Cue Biopharma, Inc. (CUE) officer Michael Vincent Meluzio reported equity compensation activity and related tax sales. He exercised performance stock units, receiving 13,647 shares of Common Stock, and sold 5,628 shares on August 13, 2026 in block trades used to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. The exercised award represents one-third of a PSU grant tied to stock-price targets, with the remaining two-thirds eligible to settle only if higher share-price hurdles are achieved within a specified performance period.

Cue Biopharma, Inc.’s Chief Executive Officer Shao-Lee Lin reported transactions in Common Stock linked to equity awards. On August 12, 2026, 109,179 performance stock units vested and settled into common shares, representing the first third of a PSU award tied to stock-price hurdles. On August 12–13, 2026, Lin sold an aggregate 58,258 shares at weighted-average prices between $26.50 and $29.87; footnotes state these were block trades executed as “sell-to-cover” transactions to satisfy tax withholding obligations on restricted stock unit vesting and are not discretionary trades. The remaining two-thirds of the PSU award may settle upon achieving closing share prices of $38.50 and $44.00 for five consecutive trading days within 24 months of grant.

A holder of CUE common stock has submitted a notice under Rule 144 describing a proposed sale of up to 58,258 shares of common stock. The shares were acquired as restricted stock units vesting under a registered compensation plan on 08/01/2026. Planned sales include 40,000 shares with an aggregate market value of 1,080,400 and 18,258 shares with an aggregate market value of 515,971, in each case through Maxim Group LLC on the NASDAQ around 08/12/2026 and 08/13/2026, respectively. The issuer has 7,264,414 shares of this class outstanding, providing context for the relative size of the proposed sale.

Cue Biopharma, Inc., a clinical-stage biopharma company, reported a sharply higher net loss while executing major licensing and financing transactions for the quarter and six months ended June 30, 2026. Collaboration revenue rose to $7.9 million for the quarter and $13.6 million year-to-date, compared with $3.0 million and $3.4 million in the prior-year periods, reflecting increased partner activity.

Operating expenses expanded substantially, with general and administrative at $46.6 million and research and development at $49.0 million in the quarter, driven by a $35.1 million upfront license cost for the Ascendant anti-IgE program (CUE-221), elevated stock-based compensation of $23.8 million in the quarter, and other one-time items. A $90.0 million loss on issuance of liability-classified warrants, partly offset by a $24.5 million fair value gain, led to a quarterly net loss of $153.1 million and a six-month loss of $158.2 million.

Cash and cash equivalents were $17.4 million at June 30, 2026, with total assets of $30.7 million and stockholders’ equity of $2.3 million. A July 2026 private placement added approximately $49.8 million of net proceeds, which, together with existing cash, is expected to fund operations for at least 12 months from issuance. A 1-for-30 reverse stock split was effected in April 2026, reducing shares outstanding but increasing the number of authorized and unissued shares.

Cue Biopharma, Inc. reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million a year earlier, driven by a preclinical milestone under its Boehringer Ingelheim collaboration. The company highlighted recent submission of an IND to the FDA for CUE-221 in food allergy and expects Phase 2 data in chronic spontaneous urticaria by the end of the third quarter of 2026. CUE-401 is expected to enter a Phase 1 study with an IND filing anticipated by year-end 2026.

Operating expenses rose sharply due to one-time items: research and development expenses were $49.0 million and general and administrative expenses were $46.6 million, reflecting approximately $20.0 million of CUE-221-related cash payments and $20.0 million of warrant fair-value expense, plus about $23.0 million of strategic transformation costs and $19.7 million of non-cash stock-based compensation. A net non-cash loss of $63.1 million related to liability-classified warrants contributed to a net loss of $153.1 million, versus $8.5 million in 2025. Cash and cash equivalents were $17.4 million as of June 30, 2026, and the company subsequently completed a $50 million private placement. Leadership was expanded with a new Chief Medical Officer and Head of R&D and a new Chief Financial Officer.